Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

After 12 weeks, weight loss with the drug was 13% of body weight, compared to 1% with placebo, which the company said was around twice the level achieved with Wegovy ... in the STEP 9 trial.

Today was supposed to mark the beginning of the end for cheaper, knockoff versions of hot weight-loss drugs. The Food and Drug Administration wants bulk production of the copycats to stop ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide ... in a 2023–24 randomized clinical trial backed by Lilly.

The company has already outlined plans for a new Phase 3 trial to test whether CagriSema can generate greater weight loss at higher doses. Novo had an early lead on Lilly, with Wegovy reaching ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

CEO Bob Bradway shared a peek at phase II results of the potential competitor to market leaders Wegovy ... step toward approval, a phase III trial of the drug. Still, Novo's stock slid more than 1 ...

Novo Nordisk said game on, as the Denmark-based drugmaker lowered prices on its obesity treatment Wegovy for those without insurance, and said it would deliver the drug to their homes. Tomi ...